88 related articles for article (PubMed ID: 8951192)
61. Pharmacokinetics of haloalkylamines: cyclization and distribution in blood in vitro and in vivo.
Ross SB
J Pharm Pharmacol; 1975 May; 27(5):322-8. PubMed ID: 239132
[TBL] [Abstract][Full Text] [Related]
62. In-vitro red blood cell partitioning of doxycycline.
Deshmukh PV; Badgujar PC; Gatne MM
Indian J Pharmacol; 2009 Aug; 41(4):173-5. PubMed ID: 20523868
[TBL] [Abstract][Full Text] [Related]
63. The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications.
Hoffman A; Goldberg A
J Pharmacokinet Biopharm; 1994 Dec; 22(6):449-68. PubMed ID: 7473076
[TBL] [Abstract][Full Text] [Related]
64. Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics.
Glassman PM; Villa CH; Ukidve A; Zhao Z; Smith P; Mitragotri S; Russell AJ; Brenner JS; Muzykantov VR
Pharmaceutics; 2020 May; 12(5):. PubMed ID: 32397513
[TBL] [Abstract][Full Text] [Related]
65. Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man.
Fleuren HL; van Rossum JM
J Pharmacokinet Biopharm; 1977 Aug; 5(4):359-75. PubMed ID: 894487
[No Abstract] [Full Text] [Related]
66. Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
Dao K; Thoueille P; Decosterd LA; Mercier T; Guidi M; Bardinet C; Lebon S; Choong E; Castang A; Guittet C; Granier LA; Buclin T
Pharmacol Res Perspect; 2020 Feb; 8(1):e00558. PubMed ID: 31990440
[TBL] [Abstract][Full Text] [Related]
67. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.
Veng-Pedersen P; Widness JA; Wang J; Schmidt RL
J Pharmacokinet Biopharm; 1997 Oct; 25(5):569-93. PubMed ID: 9679223
[TBL] [Abstract][Full Text] [Related]
68. Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?
Dash RP; Veeravalli V; Thomas JA; Rosenfeld C; Mehta N; Srinivas NR
Future Med Chem; 2021 Jan; 13(2):157-171. PubMed ID: 33275044
[TBL] [Abstract][Full Text] [Related]
69. Pharmacodynamic principles and the time course of immediate drug effects.
Holford N
Transl Clin Pharmacol; 2017 Dec; 25(4):157-161. PubMed ID: 32095468
[TBL] [Abstract][Full Text] [Related]
70. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.
Snoeck E; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Van Belle H; Woestenborghs R; Crabbé R; Van Gool R; Dupont A; Heykants J
Br J Clin Pharmacol; 1996 Nov; 42(5):605-13. PubMed ID: 8951192
[TBL] [Abstract][Full Text] [Related]
71. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.
Snoeck E; Piotrovskij V; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Woestenborghs R; Van Belle H; Van Bortel L; Van Gool R; Dupont AG; Heykants J
Br J Clin Pharmacol; 1997 Jun; 43(6):603-12. PubMed ID: 9205820
[TBL] [Abstract][Full Text] [Related]
72. Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.
Snoeck E; Piotrovskij V; Jacqmin P; Lins RL; Van Peer A; Danhof M; Woestenborghs R; Van Gool R; Dupont AG; Heykants J
Eur J Clin Pharmacol; 1997; 53(1):57-63. PubMed ID: 9349931
[TBL] [Abstract][Full Text] [Related]
73. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.
Snoeck E; Ver Donck K; Jacqmin P; Van Belle H; Dupont AG; Van Peer A; Danhof M
J Pharmacol Exp Ther; 1998 Jul; 286(1):142-9. PubMed ID: 9655853
[TBL] [Abstract][Full Text] [Related]
74. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.
Snoeck E; Jacqmin P; Van Peer A; Danhof M
J Pharmacokinet Biopharm; 1999 Jun; 27(3):257-81. PubMed ID: 10728489
[TBL] [Abstract][Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
